The c-Met β-chain is palmitoylated at the cysteine site, which enhances its stability and release from the Golgi for transport to the plasma membrane, making it a novel therapeutic target for c-Met-driven cancers (Coleman et al., 2016). The gene discussed is MET; the disease is cancer.